EGFR and non-small cell lung carcinoma: Currently, several clinical trials that co-target MET are ongoing for EGFR mutated non-small cell lung cancer (NSCLC) patients who acquired resistance to osimertinib; these include savolitinib plus osimertinib (SAVANNAH) or tepotinib plus osimertinib (INSIGHT 2).